Amgen Inc (AMGN) - Total Assets
Based on the latest financial reports, Amgen Inc (AMGN) holds total assets worth $90.59 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Amgen Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Amgen Inc - Total Assets Trend (1985–2025)
This chart illustrates how Amgen Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Amgen Inc for net asset value and shareholders' equity analysis.
Amgen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Amgen Inc's total assets of $90.59 Billion consist of 32.1% current assets and 67.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.1% |
| Accounts Receivable | $9.57 Billion | 10.6% |
| Inventory | $6.22 Billion | 6.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $22.28 Billion | 24.6% |
| Goodwill | $18.68 Billion | 20.6% |
Asset Composition Trend (1985–2025)
This chart illustrates how Amgen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Amgen Inc (AMGN) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amgen Inc's current assets represent 32.1% of total assets in 2025, a decrease from 74.5% in 1985.
- Cash Position: Cash and equivalents constituted 10.1% of total assets in 2025, down from 71.1% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 24.6% of total assets.
Amgen Inc Competitors by Total Assets
Key competitors of Amgen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Organon & Co
NYSE:OGN
|
USA | $13.00 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
Amgen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.26 | 1.66 |
| Quick Ratio | 0.90 | 0.95 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.57 Billion | $5.93 Billion | $8.43 Billion |
Amgen Inc - Advanced Valuation Insights
This section examines the relationship between Amgen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.98 |
| Latest Market Cap to Assets Ratio | 2.20 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | $90.59 Billion |
| Market Capitalization | $198.99 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Amgen Inc's assets at a significant premium (2.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Amgen Inc's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Amgen Inc (1985–2025)
The table below shows the annual total assets of Amgen Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $90.59 Billion | -1.36% |
| 2024-12-31 | $91.84 Billion | -5.47% |
| 2023-12-31 | $97.15 Billion | +49.19% |
| 2022-12-31 | $65.12 Billion | +6.47% |
| 2021-12-31 | $61.16 Billion | -2.83% |
| 2020-12-31 | $62.95 Billion | +5.43% |
| 2019-12-31 | $59.71 Billion | -10.10% |
| 2018-12-31 | $66.42 Billion | -16.93% |
| 2017-12-31 | $79.95 Billion | +3.00% |
| 2016-12-31 | $77.63 Billion | +8.45% |
| 2015-12-31 | $71.58 Billion | +3.72% |
| 2014-12-31 | $69.01 Billion | +4.36% |
| 2013-12-31 | $66.12 Billion | +21.78% |
| 2012-12-31 | $54.30 Billion | +11.10% |
| 2011-12-31 | $48.87 Billion | +12.38% |
| 2010-12-31 | $43.49 Billion | +9.73% |
| 2009-12-31 | $39.63 Billion | +8.74% |
| 2008-12-31 | $36.44 Billion | +5.21% |
| 2007-12-31 | $34.64 Billion | +2.52% |
| 2006-12-31 | $33.79 Billion | +15.33% |
| 2005-12-31 | $29.30 Billion | +0.26% |
| 2004-12-31 | $29.22 Billion | +11.63% |
| 2003-12-31 | $26.18 Billion | +7.03% |
| 2002-12-31 | $24.46 Billion | +279.57% |
| 2001-12-31 | $6.44 Billion | +19.33% |
| 2000-12-31 | $5.40 Billion | +32.42% |
| 1999-12-31 | $4.08 Billion | +11.04% |
| 1998-12-31 | $3.67 Billion | +18.07% |
| 1997-12-31 | $3.11 Billion | +12.46% |
| 1996-12-31 | $2.77 Billion | +13.68% |
| 1995-12-31 | $2.43 Billion | +22.00% |
| 1994-12-31 | $1.99 Billion | +12.95% |
| 1993-12-31 | $1.77 Billion | +28.47% |
| 1992-12-31 | $1.37 Billion | +58.79% |
| 1991-12-31 | $865.50 Million | +68.39% |
| 1990-12-31 | $514.00 Million | +66.83% |
| 1989-12-31 | $308.10 Million | +48.77% |
| 1988-12-31 | $207.10 Million | +7.42% |
| 1987-12-31 | $192.80 Million | +99.17% |
| 1986-12-31 | $96.80 Million | +3.31% |
| 1985-12-31 | $93.70 Million | -- |
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more